Glenmark to raise $200 m in Singapore bourse

Press Trust of India New Delhi | Updated on January 20, 2018 Published on May 31, 2016

Glenmark Pharmaceuticals today launched an offer on the Singapore Stock Exchange to raise up to $200 million (over ₹1,340 crore) through issue of securities.

The Mumbai-based company has decided on a regulatory floor price for conversion of the FCCBs at ₹861.84.

The company, however, did not disclose the reason for the fund-raising.

JP Morgan Securities is the sole global coordinator and book-runner for the said issue. Last year, the company’s board and shareholders had approved a plan to raise funds up to $500 million through issuance of securities, including shares or equity-linked assets, convertible bonds, warrants, and depository receipts.

Published on May 31, 2016
This article is closed for comments.
Please Email the Editor